Machine learning model predicts delayed methotrexate clearance in pediatric osteosarcoma patients
Study develops model to predict delayed drug clearance in pediatric bone cancer
A retrospective cohort study of 181 pediatric osteosarcoma patients treated with high-dose methotrexate developed a web-based prediction mod…
A new computer model predicts which children with bone cancer face delayed drug clearance, helping doctors monitor treatment risks before co…
FPGS Gene Variants Linked to Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis
Could your genes explain why methotrexate works better for some people?
A meta-analysis of 2345 rheumatoid arthritis patients on methotrexate found FPGS polymorphisms rs10106 and rs1544105 were significantly asso…
Your genes might explain why methotrexate works better for some rheumatoid arthritis patients but also raises their risk of harmful side eff…
Case report tracks urinary ADEV GluN1 levels in anti-NMDAR encephalitis patient during treatment
Single case study tracks brain inflammation marker in urine during treatment
A case report of a single female patient with anti-NMDAR encephalitis analyzed urinary astrocyte-derived extracellular vesicles (ADEVs). Lon…
Urine tests tracked brain inflammation changes in a patient with anti-NMDAR encephalitis, showing protein levels dropped over treatment and …
Meta-analysis finds nausea in 24% and abdominal pain in 20% of RA patients on methotrexate
How common is nausea and stomach pain for RA patients on methotrexate?
A systematic review and meta-analysis of 37 studies involving 19,986 adult RA patients on methotrexate found pooled prevalence rates of 24.3…
Nearly one in five rheumatoid arthritis patients taking methotrexate experience nausea or stomach pain, with about 8.5% stopping the drug du…